Training towards Personalized Antibiotic Treatment

Project Information

TIPAT

Grant agreement ID: 861323

DOI

10.3030/861323

Project closed

EC signature date 12 August 2019

Start date 1 March 2020

End date 31 August 2024

Funded under

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Total cost

€ 3 969 583,20

EU contribution

€ 3 969 583,20

Coordinated by

UNIVERSITEIT LEIDEN
Netherlands

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Websites, patent fillings, videos etc. (2)

Project Website

A public project website will be created and maintained The website will have sections for researchers and the general public including upcoming events project results partner information and publications

Videos on individual project and the overall training program

During this training ESRs will create video on their ESR project.

Documents, reports (1)

Publicity around Summer schools & Career events

Summer & Winter schools and career events will be organized, open to other PhD students for maximising TIPAT’s impact and networking opportunities. We will invite leading professionals outside TIPAT for talks and interactive discussions to enrich the workshops with additional front-line research results, career opportunities and perspectives. It is of highest priority that these events, in addition to expertise, consider diversity. JUH-IG will be in the lead for organizing one big public career event presenting the final results of TIPAT’s research projects.

Other (1)

Awarding of doctoral degrees

Every ESR will be awarded PhD degree at their host institute if completing successfully the training program according to the institutional regulations.

Publications

Peer reviewed articles (22)

Physiologically-based pharmacokinetic modelling in sepsis; a tool to elucidate how pathophysiology affects meropenem pharmacokinetics

Author(s): Salma M Bahnasawy, Neil J Parrott, Matthias Gijsen, Isabel Spriet, Lena E Friberg, Elisabet I Nielsen
Published in: International Journal of Antimicrobial Agents, 2024, Page(s) 107352, ISSN 0924-8579
Publisher: Elsevier BV
DOI: 10.1016/j.ijantimicag.2024.107352

Interspecies variability in protein binding of antibiotics basis for translational PK/PD studies—a case study using cefazolin

Author(s): Hifza Ahmed, Michaela Böhmdorfer, Sabine Eberl, Walter Jäger, Markus Zeitlinger
Published in: Antimicrobial Agents and Chemotherapy, Issue 68, 2024, ISSN 0066-4804
Publisher: American Society for Microbiology
DOI: 10.1128/aac.01647-23

Pharmacokinetic/pharmacodynamic model-based optimization of temocillin dosing strategies for the treatment of systemic infections

Author(s): Wisse van Os, Alina Nussbaumer-Pröll, Anh Duc Pham, Gert-Jan Wijnant, Perrin Ngougni Pokem, Françoise Van Bambeke, J G Coen van Hasselt, Markus Zeitlinger
Published in: Journal of Antimicrobial Chemotherapy, 2024, Page(s) dkae243, ISSN 0305-7453
Publisher: Oxford University Press
DOI: 10.1093/jac/dkae243

Bacterial growth and ceftriaxone activity in individual ascitic fluids in an in vitro model of spontaneous bacterial peritonitis

Author(s): Wisse van Os, Beatrix Wulkersdorfer, Sabine Eberl, Zoe Oesterreicher, Philipp Schwabl, Thomas Reiberger, Rafael Paternostro, Maria Weber, Birgit Willinger, Markus Zeitlinger
Published in: Frontiers in Pharmacology, Issue 14, 2023, ISSN 1663-9812
Publisher: Frontiers Media S.A.
DOI: 10.3389/fphar.2023.1124821

Impact of Continuous Infusion Meropenem PK/PD Target Attainment on C-Reactive Protein Dynamics in Critically Ill Patients With Documented Gram-Negative Hospital-Acquired or Ventilator-Associated Pneumonia

Author(s): Carla Troisi, Pier Giorgio Cojutti, Matteo Rinaldi, Tommaso Tonetti, Antonio Siniscalchi, Coen van Hasselt, Pierluigi Viale, Federico Pea
Published in: Clinical Pharmacokinetics, 2024, ISSN 0312-5963
Publisher: Adis International Ltd.
DOI: 10.1007/s40262-024-01436-6

Exploring secretory proteome and cytokine kinetic of human peripheral blood mononuclear cells exposed to methicillin-resistant Staphylococcus aureus biofilms and planktonic bacteria

Author(s): Reza Gheitasi, Daniela Röll, Mario M. Müller, Mohadeseh Naseri, Rainer König, Hortense Slevogt, Mathias W. Pletz, Oliwia Makarewicz
Published in: Frontiers in Immunology, Issue 15, 2024, ISSN 1664-3224
Publisher: Frontiers
DOI: 10.3389/fimmu.2024.1334616

Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem

Author(s): Sanz Codina, M.; Gatti, M.; Troisi, C.; Fornaro, G.; Pasquini, Z.; Trapani, F.; Zanoni, A.; Caramelli, F.; Viale, P.; Pea, F.
Published in: Pharmaceutics, 2022, ISSN 1999-4923
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics14081585

Individualized antimicrobial dose optimization: a systematic review and meta-analysis of randomized controlled trials

Author(s): Maria Sanz-Codina, Haktan Övul Bozkir, Anselm Jorda, Markus Zeitlinger
Published in: Clinical Microbiology and Infection, Issue 29, 2024, Page(s) 845-857, ISSN 1198-743X
Publisher: Blackwell Publishing Inc.
DOI: 10.1016/j.cmi.2023.03.018

Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study

Author(s): Chun Liu, Pier Giorgio Cojutti, Maddalena Giannella, Marcello Roberto, Beatrice Casadei, Gianluca Cristiano, Cristina Papayannidis, Nicola Vianelli, Pier Luigi Zinzani, Pierluigi Viale, Francesca Bonifazi, Federico Pea
Published in: Pharmaceutics, Issue 15, 2023, Page(s) 1022, ISSN 1999-4923
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics15031022

Model-based translation of results from <i>in vitro</i> to <i>in vivo</i> experiments for afabicin activity against <i>Staphylococcus aureus</i>

Author(s): Raphaël Saporta, Elisabet I Nielsen, Annick Menetrey, David R Cameron, Valérie Nicolas-Metral, Lena E Friberg
Published in: Journal of Antimicrobial Chemotherapy, 2024, ISSN 0305-7453
Publisher: Oxford University Press
DOI: 10.1093/jac/dkae334

Therapeutic drug monitoring (TDM) of β-lactam/β-lactamase inhibitor (BL/BLI) drug combinations: insights from a pharmacometric simulation study

Author(s): Amaury O’Jeanson, Elisabet I Nielsen, Lena E Friberg
Published in: Journal of Antimicrobial Chemotherapy, 2024, ISSN 0305-7453
Publisher: Oxford University Press
DOI: 10.1093/jac/dkae375

Predicting Antimicrobial Activity at the Target Site: Pharmacokinetic/Pharmacodynamic Indices versus Time–Kill Approaches

Author(s): Wisse van Os; Markus Zeitlinger
Published in: Antibiotics, Issue 1, 2021, Page(s) 1485, ISSN 2079-6382
Publisher: MDPI
DOI: 10.3390/antibiotics10121485

Biomarkers Predicting Tissue Pharmacokinetics of Antimicrobials in Sepsis: A Review

Author(s): Sanz Codina, M.; Zeitlinger, M.
Published in: Clinical Pharmacokinetics, 2022, ISSN 0312-5963
Publisher: Adis International Ltd.
DOI: 10.1007/s40262-021-01102-1

Predicting cytokine kinetics during sepsis; a modelling framework from a porcine sepsis model with live Escherichia coli

Author(s): Salma M. Bahnasawy, Paul Skorup, Katja Hanslin, Miklós Lipcsey, Lena E. Friberg, Elisabet I. Nielsen
Published in: Cytokine, Issue 169, 2024, Page(s) 156296, ISSN 1043-4666
Publisher: Academic Press
DOI: 10.1016/j.cyto.2023.156296

Comparison of ultrafiltration and microdialysis for ceftriaxone protein-binding determination

Author(s): Maria Sanz-Codina, Sebastian G Wicha, Beatrix Wulkersdorfer, Valentin Al Jalali, Wisse Van Os, Matthias G Vossen, Martin Bauer, Edith Lackner, Christoph Dorn, Markus Zeitlinger
Published in: Journal of Antimicrobial Chemotherapy, 2022, ISSN 1460-2091
Publisher: Oxford Academic
DOI: 10.1093/jac/dkac400

PKPD modelling and simulation of longitudinal meropenem in vivo effects against Escherichia coli and Klebsiella pneumoniae strains with high MIC

Author(s): Raphaël Saporta, Elisabet I. Nielsen, Jon U. Hansen, Edgars Liepinsh, Iris K. Minichmayr, Lena E. Friberg
Published in: International Journal of Antimicrobial Agents, 2024, Page(s) 107389, ISSN 0924-8579
Publisher: Elsevier BV
DOI: 10.1016/j.ijantimicag.2024.107389

Evaluation of Th2 and Th17 Immunity-Related Factors as Indicators of Brucellosis.

Author(s): Gheitasi, R.; Keramat, F.; Khosravi, S.; Hajilooi, M.; Pletz, M.; Makarewicz, O.
Published in: Front. Cell. Infect. Microbiol., 2022, ISSN 2235-2988
Publisher: Frontiers Media S. A.
DOI: 10.3389/fcimb.2021.786994

Integrative model-based comparison of target site-specific antimicrobial effects: A case study with ceftaroline and lefamulin

Author(s): Wisse van Os, Anh Duc Pham, Sabine Eberl, Iris K. Minichmayr, J.G. Coen van Hasselt, Markus Zeitlinger
Published in: International Journal of Antimicrobial Agents, Issue 63, 2024, Page(s) 107148, ISSN 0924-8579
Publisher: Elsevier BV
DOI: 10.1016/j.ijantimicag.2024.107148

Protein Binding in Translational Antimicrobial Development-Focus on Interspecies Differences

Author(s): Hifza Ahmed, Felix Bergmann, Markus Zeitlinger
Published in: Antibiotics, Issue 11, 2024, Page(s) 923, ISSN 2079-6382
Publisher: MDPI
DOI: 10.3390/antibiotics11070923

Interplay of virulence factors shapes ecology and treatment outcomes in polymicrobial infections

Author(s): C. Herzberg, E.N. van Meegen, J.G.C. van Hasselt
Published in: Mathematical Biosciences, Issue 377, 2024, Page(s) 109293, ISSN 0025-5564
Publisher: Elsevier BV
DOI: 10.1016/j.mbs.2024.109293

Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections

Author(s): Wisse van Os, Markus Zeitlinger
Published in: Journal of Antimicrobial Chemotherapy, Issue 79, 2024, Page(s) 443-446, ISSN 0305-7453
Publisher: Oxford University Press
DOI: 10.1093/jac/dkad401

Measuring Creatinine Clearance Is the Most Accurate Way for Calculating the Proper Continuous Infusion Meropenem Dose for Empirical Treatment of Severe Gram-Negative Infections among Critically Ill Patients

Author(s): Carla Troisi, Pier Giorgio Cojutti, Matteo Rinaldi, Cristiana Laici, Antonio Siniscalchi, Pierluigi Viale, Federico Pea
Published in: Pharmaceutics, Issue 15, 2023, Page(s) 551, ISSN 1999-4923
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics15020551